Bristol-Myers Squibb Company

Apr 30, 08
	NEW STORY
15:00 ET	Bristol-Myers Squibb Invites Public to Listen to Webcast of 2008 Annual Meeting
Apr 29, 08
	NEW STORY
08:30 ET	Bristol-Myers Squibb Issues $1.6 Billion of Senior Notes
Apr 26, 08
12:00 ET	BARACLUDE(R) (Entecavir) Treatment Resulted In Greater Viral Load Suppression Compared to Adefovir at 96 Weeks In Antiviral-Naive Adult Chronic Hepatitis B E-Antigen Positive Patients
Apr 24, 08
07:30 ET	Strong Double-Digit Net Sales Growth and Solid Earnings Growth Highlight First Quarter for Bristol-Myers Squibb Company
Apr 17, 08
12:00 ET	Bristol-Myers Squibb to Announce Results for the First Quarter of 2008 on April 24
Apr 08, 08
15:15 ET	U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
Mar 24, 08
16:09 ET	BARACLUDE(R) (entecavir) Data Continue to Demonstrate Low Incidence of Resistance Through Five Years of Treatment in Nucleoside-naive Chronic Hepatitis B Patients
Mar 17, 08
09:00 ET	Bristol-Myers Squibb to Present at Healthcare Conferences
Mar 05, 08
07:15 ET	Bristol-Myers Squibb Board Elects Jean-Marc Huet Senior Vice President and Chief Financial Officer
Mar 04, 08
16:30 ET	Bristol-Myers Squibb Announces Dividend
Feb 29, 08
08:30 ET	U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
Feb 27, 08
21:15 ET	Great Comebacks(R) Program Announces 2007 National Award Winner
Feb 12, 08
10:12 ET	Bristol-Myers Squibb Board Elects James M. Cornelius Chairman of the Board
Feb 06, 08
18:05 ET	CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
Jan 31, 08
07:30 ET	Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2007
Jan 22, 08
12:19 ET	Bristol-Myers Squibb Names Togo D. West, Jr. to Board of Directors
Jan 16, 08
12:00 ET	Bristol-Myers Squibb to Announce Results for the Fourth Quarter and Full Year of 2007 on January 31
Dec 17, 07
13:30 ET	European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
08:30 ET	Avista Capital Partners Agrees to Acquire Bristol-Myers Squibb Medical Imaging for Approximately $525 Million
Dec 11, 07
08:00 ET	Bristol-Myers Squibb and Gilead Sciences Expand Their Alliance to Include Commercialization of ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) in Europe
Dec 10, 07
16:26 ET	Top-Line Data Available from Three Ipilimumab Pivotal Trials in Patients with Advanced Metastatic Melanoma
Dec 05, 07
12:00 ET	Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community
Dec 04, 07
16:05 ET	Bristol-Myers Squibb Names Alan J. Lacy to Board of Directors
Nov 30, 07
13:00 ET	Bristol-Myers Squibb, New Jersey Children's Hospital Launch Center for Immune System Disorders & Infectious Diseases Including HIV/AIDS
Nov 28, 07
10:30 ET	Bristol-Myers Squibb to Webcast December 5 Business Update
Nov 27, 07
09:30 ET	World Aids Day Campaign to Shine a Light of Hope on the HIV/AIDS Epidemic in the United States
Nov 23, 07
07:00 ET	Bristol-Myers Squibb and Pierre Fabre Provide Update On Vinflunine Development Status
Nov 20, 07
11:01 ET	U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) as the First Medication for Add-On Treatment of Major Depressive Disorder (MDD)
Nov 19, 07
18:51 ET	Powerful New Efficacy Data in Moderate and Severe Hypertensive Patients Supports FDA Approval of AVALIDE(R) (Irbesartan-Hydrochlorothiazide) as the First Combination Therapy for Initial Use in Patients Likely to Need Multiple Drugs to Achieve Their Blood
Nov 15, 07
10:00 ET	ABILIFY(R) (aripiprazole) Supplemental New Drug Application for the Treatment of Pediatric Patients with Bipolar I Disorder Accepted for Priority Review by the U.S. Food and Drug Administration
Nov 14, 07
17:00 ET	New England Journal of Medicine Study Shows ERBITUX(R) Improves Survival in Advanced Colorectal Cancer
Nov 12, 07
12:55 ET	Post-Hoc Data Show Daily Activity Participation, Independence and Sleep Quality Improved in Adults with Moderate to Severe Rheumatoid Arthritis After Treatment with ORENCIA(R) (Abatacept)
Nov 09, 07
08:06 ET	Five-Year Data Demonstrate Long-Term Efficacy and Safety with ORENCIA(R) (abatacept) in Adults with Rheumatoid Arthritis Who had an Inadequate Response to Methotrexate
Nov 02, 07
09:00 ET	Ninety-one Percent of BARACLUDE(R) (entecavir) Treated Patients in a Four-Year Cohort Demonstrated Virologic Suppression to Undetectable Levels
Oct 25, 07
07:30 ET	Bristol-Myers Squibb Company Reports Financial Results for the Third Quarter and First Nine Months of 2007
Oct 17, 07
08:00 ET	Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
05:00 ET	ImClone and Bristol-Myers Squibb Announce Joint Agreement With Merck KGaA to Co-Develop and Co-Commercialize ERBITUX(R) in Japan
Oct 16, 07
17:00 ET	FDA Approves IXEMPRA(TM) (ixabepilone), a Semi-Synthetic Analog of Epothilone B, for the Treatment of Advanced Breast Cancer
Oct 08, 07
10:00 ET	Bristol-Myers Squibb to Announce Results for the Third Quarter of 2007 on October 25
Oct 02, 07
20:17 ET	Survival Data in FDA Approval for ERBITUX(R) (Cetuximab) Supports use as a Single Agent in Patients with Advanced Colorectal Cancer
Sep 28, 07
13:04 ET	Bristol-Myers Squibb Finalizes Settlement of Previously Disclosed Federal Investigation into Pricing, Sales and Marketing Practices
Sep 27, 07
13:00 ET	Jeremy Levin Joins Bristol-Myers Squibb as Senior Vice President of External Science, Technology and Licensing
09:00 ET	FDA Approves New 300mg Loading Dose Tablet for PLAVIX(R) (clopidogrel bisulfate)
Sep 24, 07
09:01 ET	Bristol-Myers Squibb to Acquire Adnexus Therapeutics
Sep 18, 07
10:13 ET	New Study Demonstrates 4 Year Olds Fed Enfamil LIPIL(R) as Infants Have Brain and Eye Outcomes Similar to Breastfed Babies
Sep 13, 07
08:00 ET	Screen and Stage Legend Phylicia Rashad Launches a Campaign Close to Her Heart
Sep 11, 07
16:48 ET	Bristol-Myers Squibb Announces Dividend
01:46 ET	ERBITUX(R) Meets Primary Endpoint of Increasing Survival in Phase III Lung Cancer Study
Sep 10, 07
09:12 ET	Bristol-Myers Squibb to Present at Bear Stearns Healthcare Conference, Reaffirms Financial Guidance
Aug 27, 07
07:30 ET	Pfizer and Bristol-Myers Squibb Finalize Agreement for Worldwide Collaboration on Metabolic Disorders Program
Aug 15, 07
09:00 ET	ConvaTec Launches Moldable Technology(TM), Custom-Fitting Skin Barriers
Jul 27, 07
16:45 ET	Bristol-Myers Squibb and ImClone Systems Significantly Expand ERBITUX Clinical Development Program
Jul 26, 07
07:00 ET	Bristol-Myers Squibb Company Reports Financial Results for the Second Quarter and First Half of 2007
Jul 23, 07
00:15 ET	Bristol-Myers Squibb's SECURE THE FUTURE(R) Program Offers New Approach to Replicate Successful HIV Treatment Support Model
Jul 12, 07
07:00 ET	Data Available From ERBITUX(R) Phase III Study in First-Line Treatment of Advanced Lung Cancer
Jul 09, 07
10:00 ET	Bristol-Myers Squibb to Announce Results for the Second Quarter of 2007 on July 26
Jul 06, 07
05:00 ET	Study Shows Ixabepilone Demonstrated Clear Activity in Patients with Metastatic Breast Cancer Resistant to Anthracycline, Taxane, and Capecitabine
Jun 29, 07
07:30 ET	Bristol-Myers Squibb Signs Agreement for Sale of Bufferin(R) and Excedrin(R) to Lion Corporation in Japan, Asia and Oceania
Jun 25, 07
16:45 ET	Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic Control in Subjects with Type 2 Diabetes Compared to Metformin Alone
10:06 ET	First Phase II Short-Term Study on Dapagliflozin Shows Results on Safety, Tolerability and Glycemic Markers in Subjects With Type 2 Diabetes
Jun 19, 07
07:00 ET	FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Ixabepilone
Jun 15, 07
08:09 ET	Investigational Study Demonstrated a Re-Establishment of Clinical Improvement with Orencia(R) (Abatacept) in Children with Juvenile Idiopathic Arthritis upon Re-Introduction of Therapy
Jun 14, 07
16:16 ET	Statement on the Deferred Prosecution Agreement Following Press Release From U.S. Attorney
Jun 12, 07
16:10 ET	Bristol-Myers Squibb Announces Dividend
Jun 11, 07
07:00 ET	FDA Accepts and Grants Priority Review of Erbitux(R) (Cetuximab) sBLA for Overall Survival in Patients With Advanced Colorectal Cancer
Jun 05, 07
08:00 ET	ABILIFY(R) (aripiprazole) Supplemental New Drug Application for Pediatric Patients With Schizophrenia Accepted for Priority Review by the U.S. Food and Drug Administration
Jun 03, 07
10:00 ET	Phase III Ixabepilone Study Demonstrated Significant Improvement in Progression-Free Survival in Patients With Advanced Metastatic Breast Cancer
May 10, 07
16:41 ET	Bristol-Myers Squibb Announces Agreement in Principle to Resolve Federal Antitrust Investigation
May 09, 07
07:00 ET	Bristol-Myers Squibb Enters Cardiovascular Disease Collaboration With Isis Pharmaceuticals
May 07, 07
12:00 ET	'AIM for the B' Public Education Program To Raise Awareness of Chronic Hepatitis B Among Communities Most Affected by the Disease
Apr 26, 07
07:30 ET	Bristol-Myers Squibb Company Reports First Quarter 2007 Financial Results
07:30 ET	James M. Cornelius Elected Bristol-Myers Squibb CEO
07:00 ET	Bristol-Myers Squibb and Pfizer Announce Worldwide Collaboration to Develop and Commercialize Anticoagulant and Metabolic Compounds
Apr 16, 07
11:00 ET	Broadway Actress/HIV Advocate, Sheryl Lee Ralph, Unveils Winning Photographs in Contest Communicating Personal Experiences with HIV/AIDS Through Photography
Apr 13, 07
08:10 ET	BARACLUDE(R) (entecavir) Therapy Resulted in Undetectable Levels of Hepatitis B Virus in Cohort of Patients Who Re-Started Treatment
Apr 04, 07
02:00 ET	Survival Data Available From ERBITUX(R) Study in First-Line Treatment of Advanced Head and Neck Cancer
Mar 06, 07
17:05 ET	Bristol-Myers Squibb Announces Dividend
15:45 ET	Bristol-Myers Squibb Names Michael Grobstein to Board of Directors
Feb 16, 07
16:29 ET	Bristol-Myers Squibb Completes Land Acquisition for New Biologics Facility
Feb 15, 07
13:00 ET	Bristol-Myers Squibb Names Sandra Leung Senior Vice President and General Counsel
Feb 05, 07
02:00 ET	ImClone Systems Incorporated and Bristol-Myers Squibb Announce Application In Japan for Use of ERBITUX in Metastatic Colorectal Cancer
Jan 17, 07
10:00 ET	Bristol-Myers Squibb to Announce Results for the Fourth Quarter and Full Year of 2006 on January 25
Jan 11, 07
07:00 ET	Bristol-Myers Squibb and AstraZeneca Announce Worldwide Collaboration to Develop and Commercialize Diabetes Compounds
Jan 10, 07
02:00 ET	ERBITUX(R) Phase III Study Meets Primary Endpoint In First-Line Treatment of Metastatic Colorectal Cancer
Dec 28, 06
13:38 ET	Canadian Federal Court of Appeals Rules in sanofi-aventis' Favor in the Canadian Plavix Notice of Compliance Proceedings
Dec 27, 06
00:01 ET	Bristol-Myers Squibb and Otsuka Pharmaceutical Co., Ltd. Announce Exclusive Licensing Agreement for Diabetes Compound Saxagliptin in Japan
Dec 21, 06
08:00 ET	Bristol-Myers Squibb Announces Agreement In Principle to Settle Federal Investigation Into Pricing, Sales And Marketing Practices
Dec 18, 06
07:00 ET	Exelixis and Bristol-Myers Squibb Sign New Collaboration Agreement to Discover and Develop Novel Oncology Compounds
Dec 13, 06
10:00 ET	Bristol-Myers Squibb to Hold Investor Teleconference to Discuss Data Presented at ASH Meeting
Dec 12, 06
08:00 ET	ABILIFY(R) (Aripiprazole) Injection for Intramuscular Use for Adults With Agitation Associated With Schizophrenia or Bipolar Mania Now Available
Dec 11, 06
08:30 ET	STUDY OF SPRYCEL(R) (DASATINIB) OR 800 MG OF GLEEVEC(R)* (IMATINIB MESYLATE) SHOWS PATIENTS TREATED WITH SPRYCEL ACHIEVED HIGH CYTOGENETIC RESPONSES AND PROLONGED PROGRESSION-FREE SURVIVAL
08:19 ET	STUDY SHOWS SPRYCEL(R) (DASATINIB) 100 MG ONCE A DAY PROVIDES RESPONSES SIMILAR TO THOSE IN PATIENTS TAKING APPROVED 70 MG TWICE A DAY DOSE, WITH REDUCED INCIDENCE OF SIDE EFFECTS
Dec 08, 06
13:27 ET	Preliminary Injunction Against Apotex Upheld on Appeal
Dec 05, 06
16:05 ET	Bristol-Myers Squibb Announces Dividend
Dec 01, 06
07:30 ET	Bristol-Myers Squibb Company Announces Voluntary Delisting From NYSE Arca
Nov 27, 06
14:10 ET	Bristol-Myers Squibb and The National AIDS Fund Announce World AIDS Day Campaign to Shine a Light on the HIV/AIDS Epidemic in the United States
Nov 20, 06
12:23 ET	Crohn's and Colitis Foundation of America and ConvaTec Recognize Young Patients With Inflammatory Bowel Disease
07:45 ET	Bristol-Myers Squibb Announces Results of the Tender Offer for Its 5.75% Notes Due October 1, 2011
Nov 17, 06
10:02 ET	Catholic Medical Mission Board Announces Donation of Lifesaving Pediatric Drugs
Nov 16, 06
18:42 ET	Bristol-Myers Squibb Prices Tender Offer on its 5.75% Notes Due October 1, 2011
Nov 14, 06
18:19 ET	Bristol-Myers Squibb Company Announces Promotion of Andrew Bonfield and Elliott Sigal to Executive Vice Presidents
17:10 ET	ORENCIA(R) (abatacept) or REMICADE(R)(infliximab) Demonstrated Superior Efficacy to Placebo at Six Months With ORENCIA Demonstrating Both Durable Efficacy and a More Favorable Safety Profile Through 12 Months
Nov 13, 06
15:27 ET	ORENCIA(R) (abatacept) Data Demonstrated Improvement in Children and Adolescents With Juvenile Idiopathic Arthritis as Measured by the Validated ACR Pediatric Criteria
Nov 09, 06
02:30 ET	Bristol-Myers Squibb Company Announces Debt Tender Offer
Nov 06, 06
05:00 ET	Survival Data Available from Two Randomized ERBITUX Studies in Metastatic Colorectal Cancer
Oct 30, 06
15:15 ET	Three-Year Data Showed Low Incidence of BARACLUDE(R) (Entecavir) Resistance in Nucleoside-Naive Chronic Hepatitis B Patients
15:00 ET	BARACLUDE(R) (Entecavir) Demonstrated Viral Suppression to Undetectable Levels in Most Patients in a Three-Year Cohort
08:00 ET	Study Shows Treatment with BARACLUDE(R) (Entecavir) Resulted in Greater Viral Load Reductions Compared to Adefovir in Antiviral Naive Chronic Hepatitis B E-Antigen Positive Patients
Oct 26, 06
07:31 ET	Bristol-Myers Squibb Company Reports Financial Results for the Third Quarter and First Nine Months of 2006
Oct 16, 06
11:05 ET	Bristol-Myers Squibb to Announce Results for the Third Quarter of 2006 on October 26
Oct 09, 06
02:30 ET	Bristol-Myers Squibb, Gilead Sciences and Merck & Co. Submit Marketing Authorisation Application for ATRIPLA(TM) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg) to European Medicines Agency
Sep 21, 06
17:29 ET	Plavix(R) Preliminary Injunction Appeal
Sep 13, 06
02:30 ET	Bristol-Myers Squibb Company and Medivir AB Announce Worldwide Collaboration to Develop and Commercialize MIV-170 for the Treatment of HIV-1 Infection in Adults
Sep 12, 06
14:28 ET	Bristol-Myers Squibb Announces Dividend
Sep 11, 06
17:26 ET	Bristol-Myers Squibb Board of Directors Establish Science and Technology Committee of the Board
17:24 ET	Bristol-Myers Squibb Names R. Sanders Williams, M.D. to Board of Directors
Sep 01, 06
19:33 ET	Bristol-Myers Squibb Lowers 2006 Earnings Per Share Guidance
Aug 17, 06
09:56 ET	Bristol-Myers Squibb and Otsuka Pharmaceutical Company Launch New Rapidly Disintegrating Oral Antipsychotic Medication ABILIFY(R) DISCMELT(TM) (aripiprazole)
Aug 14, 06
13:45 ET	Motion Filed for Preliminary Injunction in PLAVIX(R) Patent Infringement Case
Aug 13, 06
11:30 ET	Clinical Results Show Integrating Medical Care With Community Supports Is Key to Successful Outcomes for HIV Patients in Resource-Limited Settings
Jul 28, 06
20:00 ET	PLAVIX(R) Litigation Settlement Fails to Receive Antitrust Clearance From States Attorneys General
Jul 27, 06
08:17 ET	Bristol-Myers Squibb Company Reports Financial Results for the Second Quarter and First Half of 2006
Jul 18, 06
08:45 ET	Bristol-Myers Squibb to Announce Results for the Second Quarter of 2006 on July 27
Jul 11, 06
16:46 ET	Bristol-Myers Squibb Names Vicki L. Sato to Board of Directors
Jun 28, 06
16:58 ET	FDA Approves SPRYCEL(TM) (dasatinib) With Two Indications
Jun 25, 06
11:00 ET	Update on Plavix(R) Litigation Settlement
Jun 23, 06
09:00 ET	New Two-Year ORENCIA(R) (abatacept) AIM Data Presented at Annual EULAR Congress
Jun 14, 06
17:15 ET	Bristol-Myers Squibb Announces Dividend
Jun 03, 06
16:00 ET	Data From a Randomized Phase II Study of Dasatinib or 800 Mg/Day Imatinib- Mesylate (Gleevec(R)) Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology
Jun 02, 06
14:57 ET	Bristol-Myers Squibb Issues Statement on Oncologic Drugs Advisory Committee Vote in Favor of Investigational Drug Dasatinib
May 31, 06
11:00 ET	Bristol-Myers Squibb to Hold Investor Teleconference to Discuss ASCO Highlights
May 25, 06
14:03 ET	Six-Month Study Evaluated Effectiveness of Aripiprazole and Standard of Care In Management of Community-Treated Patients with Schizophrenia
May 23, 06
11:45 ET	96-Week Viral Suppression Data From Two Studies Presented for BARACLUDE(R) (entecavir) in Chronically-Infected Hepatitis B Patients
May 16, 06
09:00 ET	ABILIFY(R) (Aripiprazole) Demonstrated Efficacy as Maintenance Therapy In Adults with Bipolar I Disorder Following Treatment for a Recent Manic or Mixed Episode
May 05, 06
16:41 ET	U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) Supplemental Biologics License Application (sBLA) for Third-Party Manufacturing Facility Lonza Biologics Inc.
Apr 27, 06
07:30 ET	Bristol-Myers Squibb Company Reports First Quarter 2006 Financial Results
Apr 17, 06
13:00 ET	Bristol-Myers Squibb Company Names David I. Johnson President of ConvaTec
08:30 ET	Bristol-Myers Squibb to Announce Results For The First Quarter of 2006 on April 27
Mar 21, 06
16:30 ET	Sanofi-aventis and Bristol-Myers Squibb Announce Agreement to Settle U.S. PLAVIX(R) Litigation with Apotex Subject to Certain Conditions
Mar 08, 06
17:01 ET	The New England Journal of Medicine Reports BARACLUDE(TM) (entecavir) Demonstrated Benefits Over Lamivudine In Treating Chronically Infected Hepatitis B Patients at 48 Weeks
08:02 ET	Bristol-Myers Squibb Plans to Build Biologics Facility in the U.S.
Mar 07, 06
16:01 ET	Bristol-Myers Squibb Announces Dividend
08:01 ET	FDA Grants Priority Review for Bristol-Myers Squibb's Investigational Oncology Treatment Dasatinib
Mar 01, 06
19:29 ET	FDA Approves ERBITUX(R) (Cetuximab) for Treatment of Head and Neck Cancer
Feb 28, 06
07:54 ET	U.S. Food and Drug Administration Approves EMSAM(R) (selegiline transdermal system), the First Transdermal Patch for the Treatment of Major Depressive Disorder
Feb 24, 06
04:00 ET	Swaziland's First Children's HIV/AIDS Medical Center Opens; Building Treatment Capacity in the World's Hardest Hit Country
Feb 21, 06
09:20 ET	Mead Johnson Recalls One Batch of Gentlease(TM) Powder Infant Formula in 24 Ounce Cans
Feb 09, 06
13:00 ET	New 48 Week Clinical Trial Data Reported Comparing REYATAZ(R) (Atazanavir Sulfate), With or Without Ritonavir, in Treatment-Naive Patients
08:30 ET	Bristol-Myers Squibb Announces Preliminary Approval of Settlement in Shareholder Class Action Litigation
Jan 25, 06
06:59 ET	Bristol-Myers Squibb Company Reports Financial Results for the Fourth Quarter and Twelve Months of 2005 and Announces EPS Guidance for 2006
Jan 23, 06
07:00 ET	Bristol-Myers Squibb Announces Litigation Reserve
Jan 18, 06
11:04 ET	Bristol-Myers Squibb to Announce Results for the Fourth Quarter and 12 Months of 2005 on January 25
Jan 03, 06
16:00 ET	Study Reported in JAMA Concludes That High Level of Hepatitis B Virus in Patients With Chronic Hepatitis B Infection Predicts Increased Risk For Liver Cancer
Dec 28, 05
15:45 ET	Bristol-Myers Squibb Submits New Drug Application for Dasatinib
Dec 22, 05
08:04 ET	Bristol-Myers Squibb Statement on Muraglitazar, an Investigational Oral Treatment for Type 2 Diabetes
Dec 20, 05
08:04 ET	Crohn's Patient Robert Hill to Scale Antarctic Summit for Intestinal Disease Awareness
Dec 16, 05
10:00 ET	More Than 100,000 People Unite to Support AIDS Prevention and Care Programs Through Bristol-Myers Squibb 2005 World AIDS Day Campaign
Dec 12, 05
13:00 ET	Bristol-Myers Squibb Updates the Investment Community on the Continued Execution of the Company's Strategy
Dec 06, 05
17:00 ET	Bristol Myers Squibb Company Announces Dividend
Dec 05, 05
13:00 ET	Bristol-Myers Squibb Company to Webcast December 12 Business Update
Dec 02, 05
14:29 ET	Bristol-Myers Squibb Promotes John E. Celentano to President of Health Care Group
Dec 01, 05
01:00 ET	First Children's HIV/AIDS Medical Center Opens in Lesotho; Public-Private Partnership Provides Staffing, Funding
Nov 14, 05
09:04 ET	BARACLUDE(TM) (entecavir) Two-year Data Analysis Did Not Detect Emergence of Resistance in Nucleoside-Naive Chronic Hepatitis B Patients
Oct 20, 05
14:18 ET	Distinguished Achievement Awards Go to Seven Leading Researchers for Groundbreaking Discoveries; $6.5 Million in No-Strings-Attached Grants Support 13 Scientists for Cutting Edge Biomedical Research Across Three Continents
Oct 18, 05
08:04 ET	Bristol-Myers Squibb and Merck Joint Statement on Regulatory Status of PARGLUVA(TM) (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes
Oct 11, 05
13:10 ET	Bristol-Myers Squibb Names Richard Willard Senior Vice President and General Counsel
Sep 27, 05
17:30 ET	Bristol-Myers Squibb Invites Others to Join in Expansion of Pediatric AIDS Corps in Africa
Sep 20, 05
09:20 ET	Bristol-Myers Squibb Company Announces Planned Departure of Donald Hayden, Executive Vice President and President, Americas
09:18 ET	Bristol-Myers Squibb Company Reorganizes Operating Units, Promoting Lamberto Andreotti to Executive Vice President and President, Worldwide Pharmaceuticals
08:00 ET	Bristol-Myers Squibb Tour of Hope(TM) Team Joins Lance Armstrong to Kick Off 3,300-Mile Cycling Journey to Raise Awareness About Cancer Clinical Trials
Sep 13, 05
17:43 ET	Bristol-Myers Squibb Announces Dividend
16:30 ET	Bristol-Myers Squibb Names Louis J. Freeh to Board of Directors
Sep 09, 05
15:20 ET	Bristol-Myers Squibb and Merck Joint Statement on FDA Advisory Committee Vote on PARGLUVA(TM) (Muraglitazar), an Investigational Oral Treatment for Type 2 Diabetes
Sep 06, 05
16:13 ET	Bristol-Myers Squibb Statement on FDA Advisory Committee Vote on ORENCIA(R) (Abatacept), an Investigational Selective Modulator of T-Cell Co-Stimulation for Rheumatoid Arthritis
Aug 31, 05
16:30 ET	Bristol-Myers Squibb Company Closes Previously Announced Sale of U.S. and Canadian Consumer Medicines Business
Aug 30, 05
07:00 ET	ImClone Systems Incorporated and Bristol-Myers Squibb File Supplemental Biologics License Application for ERBITUX(R) for Treatment of Head and Neck Cancer
Aug 10, 05
13:34 ET	New Enfamil(R) Gentlease(TM) LIPIL(R) Now Available for Babies With Fussiness or Gas
Jul 28, 05
06:58 ET	Bristol-Myers Squibb Announces Financial Results for the Second Quarter and First Half of 2005, with Businesses on Plan, Led By Pharmaceutical Growth Drivers
Jul 19, 05
16:07 ET	Bristol-Myers Squibb Company to Announce Results for the Second Quarter and First Half of 2005 on July 28
Jul 14, 05
16:12 ET	Bristol-Myers Squibb Signs Agreement for Previously Announced Sale of Its U.S. and Canadian Consumer Medicines Business
Jun 21, 05
22:00 ET	Bristol-Myers Squibb Company Signs Manufacturing Agreement With Celltrion
Jun 20, 05
12:13 ET	Bristol-Myers Squibb Tour of Hope(TM) Announces Team of Cancer Advocates to Join Lance Armstrong in Cross Country Journey in Support of Cancer Research
Jun 15, 05
14:35 ET	Bristol-Myers Squibb Announces Agreement With the U.S. Attorney's Office in New Jersey
14:35 ET	James D. Robinson III Elected Non-Executive Chairman Of The Board Of Bristol-Myers Squibb; Peter R. Dolan Continues As CEO
Jun 12, 05
17:20 ET	Phase III and II Data for Investigational Medicine PARGLUVA(TM) (muraglitazar) Highlighted in Late-Breaking Presentation at Annual Scientific Sessions of the American Diabetes Association
Jun 09, 05
08:31 ET	New Phase III Efficacy Data on Investigational Biologic Abatacept Presented at EULAR Meeting
May 25, 05
08:31 ET	New Investigational Data Using Intramuscular Administration of Aripiprazole in Patients with Acute Bipolar Mania and Schizophrenia
May 20, 05
16:46 ET	New Study Shows Investigational Compound Muraglitazar Significantly Lowered Blood Glucose Levels As Measured By A1C Reduction in Patients With Type 2 Diabetes
May 11, 05
16:56 ET	Bristol-Myers Squibb Closes Previously Announced Sale of Its OTN Distribution Business to One Equity Partners LLC
May 09, 05
17:44 ET	Bristol-Myers Squibb Revises Certain Financial Information With Filing of Its First Quarter 2005 Form 10-Q
09:00 ET	'Aim for the B' Targets Need to Increase Education and Awareness for Chronic Hepatitis B
Apr 28, 05
07:11 ET	Bristol-Myers Squibb Reports First Quarter 2005 Results in Line With Expectations and Increased Investment in Research and Growth Products
Apr 27, 05
09:02 ET	Bristol-Myers Squibb Announces Settlement of Derivative Litigation Against Current and Former Officers and Directors
Apr 19, 05
09:57 ET	Bristol-Myers Squibb to Announce First Quarter Results for 2005 on April 28, 2005
Apr 05, 05
06:35 ET	Bristol-Myers Squibb Joins National Program to Help Uninsured Americans Get the Prescription Medications They Need
Apr 01, 05
08:30 ET	Bristol-Myers Squibb Announces Results of Tender Offer And Intention to Redeem All Remaining 2006 Notes
Mar 30, 05
17:30 ET	Bristol-Myers Squibb Prices Tender Offer
Mar 29, 05
19:38 ET	U.S. Food and Drug Administration (FDA) Approves BARACLUDE(TM) (entecavir) for Treatment of Chronic Hepatitis B
Mar 23, 05
09:01 ET	Bristol-Myers Squibb Announces Debt Tender Offer
Mar 22, 05
13:13 ET	Bristol-Myers Squibb Extends Assistance to State AIDS Drug Assistance Programs
10:54 ET	Lance Armstrong and Cancer Community Seek Cyclists for 2005 Bristol-Myers Squibb Tour of Hope(TM) National Team
Mar 07, 05
11:17 ET	ABILIFY(R) (aripiprazole) Granted Approval for New Indication
Mar 01, 05
16:32 ET	Bristol-Myers Squibb Announces Dividend
Jan 27, 05
07:33 ET	Bristol-Myers Squibb Announces Fourth Quarter and Twelve Months Sales and Earnings for 2004
Jan 24, 05
12:00 ET	Bristol-Myers Squibb to Announce Fourth Quarter and Twelve Months Results for 2004 on January 27, 2005
Jan 13, 05
13:24 ET	Sod-Turning Ceremony Marks Start of Construction of First Pediatric HIV/AIDS Medical Center in Swaziland
Jan 12, 05
10:45 ET	Bristol-Myers Squibb Plans to Divest U.S. and Canadian Consumer Medicines Business
Jan 03, 05
17:23 ET	Bristol-Myers Squibb Names James M. Cornelius to Board of Directors
Dec 23, 04
12:00 ET	Bristol-Myers Squibb Provides Regulatory Update for Muraglitazar and Abatacept
Dec 20, 04
08:30 ET	Bristol-Myers Squibb and Gilead Sciences Establish U.S. Joint Venture to Develop and Commercialize Fixed-Dose Combination of Three HIV Medicines
Dec 14, 04
09:23 ET	Bristol-Myers Squibb to Sell Oncology Therapeutics Network
Dec 10, 04
16:13 ET	Bristol-Myers Squibb Announces Intent to Pursue FDA Approval of Pravachol(R) (pravastatin sodium) as an OTC Cholesterol-Lowering Therapy
Dec 07, 04
17:54 ET	Bristol-Myers Squibb Announces Dividend
Dec 05, 04
19:30 ET	Phase I Study Results of Investigational Agent BMS-354825 in Patients With Imatinib-Resistant or Intolerant Chronic Myelogenous Leukemia Presented at the 46th Annual Meeting of the American Society of Hematology
Nov 30, 04
16:08 ET	Bristol-Myers Squibb Invites Yahoo!'s Global Audience to Shine a Light on the HIV/AIDS Crisis on World AIDS Day
Nov 17, 04
09:15 ET	Bristol-Myers Squibb Showcases Pipeline at Research and Development Overview Meeting
Nov 11, 04
10:00 ET	Bristol-Myers Squibb to Host Research and Development Overview with Financial Analysts on November 17, 2004
Nov 08, 04
06:01 ET	Bristol-Myers Squibb Company and Medarex Form Global Development and Commercialization Collaboration for MDX-010
Nov 01, 04
10:40 ET	Bristol-Myers Squibb Foundation and China Foundation for Hepatitis Prevention and Control Collaborate to Fight One of China's Most Pressing Health Problems
10:35 ET	UPDATE: Investigational Hepatitis B Agent entecavir Demonstrated Statistically Significant Improvement Over lamivudine in Chronically Infected Hepatitis B Patients
Oct 29, 04
17:01 ET	Use of Investigational Agent Entecavir Demonstrated Statistically Significant Improvement in Liver Histology and Viral Suppression Compared to Lamivudine in Chronically Infected Hepatitis B E-Antigen (HBeAg) Positive Patients
07:53 ET	Bristol-Myers Squibb Announces Third Quarter and Nine Months Sales and Earnings for 2004
Oct 28, 04
15:30 ET	Bristol-Myers Squibb Appoints Dr. Elliott Sigal Chief Scientific Officer and President of The Pharmaceutical Research Institute
Oct 27, 04
06:00 ET	Pediatric HIV/AIDS Medical Centers to be Built in African Nations of Lesotho and Swaziland
Oct 26, 04
10:08 ET	Bristol-Myers Squibb Mourns the Loss of James B.D. Palmer, F.R.C.P., Chief Scientific Officer and President of the Pharmaceutical Research Institute
Oct 25, 04
16:30 ET	Bristol-Myers Squibb to Announce Third Quarter Earnings on October 29, 2004
Oct 22, 04
12:52 ET	Elliott Sigal Named Acting President of Bristol-Myers Squibb Pharmaceutical Research Institute
Oct 18, 04
08:32 ET	Phase III Clinical Trial Results of Investigational Biologic Abatacept Demonstrated Clinical Activity in Patients With Rheumatoid Arthritis
Oct 17, 04
18:15 ET	Phase III Clinical Trial Results of Investigational Biologic Abatacept Demonstrated Clinical Activity in Patients With Rheumatoid Arthritis
Oct 06, 04
11:46 ET	Expecta(TM) LIPIL(R) DHA Supplement Now Available For Pregnant and Nursing Women
Oct 04, 04
10:02 ET	Bristol-Myers Squibb Submits Applications in U.S. and Europe to Market Entecavir, an Investigational Antiviral Treatment For Chronic Hepatitis B Infection
Sep 28, 04
09:37 ET	Parents Can Start Saving for Their Children's Education When Purchasing Enfamil(R) Formulas
Sep 22, 04
11:01 ET	Bristol-Myers Squibb Tour of Hope(TM) Team, Lance Armstrong to Embark on Cross-Country Cycling Journey from Los Angeles
Sep 14, 04
17:04 ET	Bristol-Myers Squibb Announces Dividend
Aug 26, 04
10:00 ET	New Long-Term Data Provide Guidance on the Use of Sustiva(R) (Efavirenz) in HIV-Treatment-Naive Patients
Aug 04, 04
12:00 ET	Bristol-Myers Squibb Statement on SEC Settlement
Aug 02, 04
08:50 ET	Bristol-Myers Squibb Company Extends Exchange Offer on 4.00% Senior Notes
Jul 30, 04
10:04 ET	Bristol-Myers Squibb to Settle Securities Class Action Litigation
Jul 29, 04
07:12 ET	Bristol-Myers Squibb Announces Second Quarter and Six Months Sales and Earnings for 2004
Jul 22, 04
15:36 ET	Bristol-Myers Squibb to Announce 2004 2nd Quarter Earnings on July 29, 2004
Jul 14, 04
08:34 ET	REYATAZ(R) (atazanavir sulfate) Granted Approval For Use With Low-Dose Ritonavir in Treatment-Experienced HIV-Infected Patients
Jul 12, 04
08:22 ET	New Mali Center Joins Five Other Novel HIV/AIDS Community-Based Treatment Support Programs
Jun 28, 04
09:06 ET	Bristol-Myers Squibb Announces Expected Increases In Legal Reserves Of $400 Million
Jun 08, 04
17:00 ET	Bristol-Myers Squibb Announces Dividend
Jun 07, 04
07:02 ET	ABILIFY(R) (aripiprazole) Approved For Marketing in Europe for the Treatment of Schizophrenia
Jun 01, 04
09:49 ET	Bristol-Myers Squibb Tour of Hope(TM) Announces 20 Cancer Survivors, Loved Ones and Experts to Join Lance Armstrong in Raising Awareness of Cancer Clinical Trials
May 17, 04
08:32 ET	Bristol-Myers Squibb and Solvay Pharmaceuticals in Development and Commercialization Agreement Involving Novel Obesity Compound
May 07, 04
15:44 ET	Lesotho Launches Its Public Sector ARV Learning Center With $3.9 Million In Support From Bristol-Myers Squibb's Secure the Future Program
May 05, 04
15:01 ET	New Data and Analyses Demonstrate ABILIFY(R) (Aripiprazole) Effective at Treating Patients With Acute Manic and Mixed Episodes of Bipolar Disorder
12:00 ET	Clinical Study Shows Intramuscular Administration of Aripiprazole (Abilify(R)) Significantly Improves Acute Agitation in Patients With Schizophrenia
Apr 28, 04
07:37 ET	Bristol-Myers Squibb Announces First Quarter Sales and Earnings For 2004
07:14 ET	Bristol-Myers Squibb and Merck Announce Global Development And Commercialization Alliance for Muraglitazar, a Novel Compound For Diabetes
Apr 27, 04
07:54 ET	Bristol-Myers Squibb Statement on Paraplatin Settlement
Apr 21, 04
12:00 ET	Bristol-Myers Squibb to Announce 2004 First Quarter Earnings on April 28, 2004
08:35 ET	Bristol-Myers Squibb and Metrika Announce Exclusive U.S. Supply Agreement for A1cNow(R) Diabetes Monitor
Apr 20, 04
08:03 ET	Bristol-Myers Squibb and Pierre Fabre Medicament S.A. Enter Into Agreement to Develop and Commercialize Oncology Treatment Javlor(R) (vinflunine)
Apr 15, 04
12:19 ET	Cutting Edge HIV/AIDS Monitoring Research Funded by Bristol-Myers Squibb Leads to Significant Cost Savings for African Nations
Apr 06, 04
09:14 ET	Bristol-Myers Squibb Announces Acquisition of Acordis Speciality Fibres Business
Mar 31, 04
09:50 ET	Bristol-Myers Squibb Statement Regarding Paraplatin Pediatric Submission and Federal Appeals Court Reversal on Patent
Mar 17, 04
09:49 ET	Lance Armstrong and Cancer Community Seek Cyclists to Participate in 2004 Bristol-Myers Squibb Tour of Hope(TM)
Mar 08, 04
10:54 ET	New Study Demonstrates the Benefits of Intensive Statin Therapy In Patients Hospitalized with Acute Coronary Syndrome
Mar 02, 04
17:47 ET	Bristol-Myers Squibb Announces Dividend
Feb 12, 04
16:39 ET	ERBITUX(TM) (Cetuximab) Receives FDA Approval to Treat Irinotecan Refractory Or Intolerant Metastatic Colorectal Cancer
Feb 10, 04
10:31 ET	Women In Government Announces Partnership With Bristol-Myers Squibb Foundation to Convene First Ever Summit of State Offices of Women's Health
Jan 29, 04
08:16 ET	Bristol-Myers Squibb Announces Fourth Quarter And Twelve Months Sales and Earnings for 2003
Jan 27, 04
12:54 ET	Bristol-Myers Squibb to Announce 2003 Fourth Quarter and Full Year Earnings On January 29, 2004
10:47 ET	$4.6 Million in 'Freedom to Discover' Grants Awarded To 10 Leading Medical Research Institutions
Dec 16, 03
01:45 ET	Mead Johnson & Company Confirms Sale of Global Adult Nutritional Business
Dec 09, 03
17:06 ET	Bristol-Myers Squibb Announces Dividend
Dec 03, 03
12:53 ET	Bristol-Myers Squibb Commits to Funding New Pediatric HIV/AIDS Center in Africa
Nov 24, 03
06:30 ET	ImClone Systems Incorporated and Bristol-Myers Squibb File New Drug Submission With Health Canada for Use of ERBITUX(TM) (Cetuximab) for Treatment of EGFR-Expressing Irinotecan-Refractory Metastatic Colorectal Cancer
Oct 23, 03
08:18 ET	Bristol-Myers Squibb Announces Third Quarter and Nine Months Sales and Earnings for 2003
Oct 17, 03
09:45 ET	Bristol-Myers Squibb to Announce Third Quarter Earnings On October 23, 2003
Oct 13, 03
08:31 ET	Bristol-Myers Squibb and Corgentech Enter Global Agreement to Develop and Commercialize Novel Cardiovascular Therapy
Oct 11, 03
17:20 ET	Lance Armstrong Leads the Bristol-Myers Squibb Tour of Hope(TM) To Raise Awareness About the Promise of Cancer Research
Oct 10, 03
19:55 ET	ImClone Systems and Bristol-Myers Squibb Announce Acceptance of ERBITUX(TM) (Cetuximab) Biologics License Application for Review by the U.S. Food and Drug Administration
Sep 29, 03
16:35 ET	Public Festival to Welcome Lance Armstrong & the Tour of Hope Team to Washington After Cross-Country Cycling Journey Grand Finale - Saturday, October 18 - The Ellipse
Sep 24, 03
17:47 ET	Bristol-Myers Squibb Announces Offering of Convertible Senior Debentures
Sep 23, 03
08:30 ET	Bristol-Myers Squibb Launches Comprehensive Line of ChoiceDM(TM) Diabetic Care Products
Sep 10, 03
08:31 ET	Bristol-Myers Squibb and QDose Announce Collaboration to Develop Inhaled Insulin for the Treatment of Diabetes
Sep 09, 03
17:18 ET	Bristol-Myers Squibb Announces Dividend
Sep 08, 03
15:32 ET	FDA Approves ABILIFY(TM) (Aripiprazole) Supplemental New Drug Application (sNDA) for Maintaining Stability in Patients With Schizophrenia
Sep 02, 03
07:31 ET	Bristol-Myers Squibb Provides Update on Garenoxacin Development
Aug 27, 03
08:00 ET	Bristol-Myers Squibb and Flamel Technologies Announce Licensing Agreement For Basulin(R)
Aug 21, 03
12:08 ET	Bristol-Myers Squibb Tour of Hope(TM) Announces Team Members To Ride Across America, Joining Lance Armstrong To Raise Awareness of Cancer Research
Aug 14, 03
13:27 ET	ImClone Systems Incorporated and Bristol-Myers Squibb Announce Submission of Biologics License Application for ERBITUX(TM) (Cetuximab) To Treat Irinotecan-Refractory Metastatic Colorectal Cancer
Jul 24, 03
08:49 ET	Bristol-Myers Squibb Announces Second Quarter and Six Months Sales and Earnings for 2003
Jul 22, 03
16:47 ET	Bristol-Myers Squibb Reviews Sales And Marketing Compliance
Jul 21, 03
15:00 ET	Bristol-Myers Squibb to Announce Second Quarter Earnings on July 24, 2003
Jul 16, 03
11:30 ET	Supplemental New Drug Application Submitted for ABILIFY(TM)(aripiprazole) For the Treatment of Acute Bipolar Mania
Jul 01, 03
16:03 ET	Bristol-Myers Squibb and Lance Armstrong Partner in Unprecedented Tour of Hope(TM) to Raise Awareness of Cancer Research
Jun 25, 03
08:30 ET	Bristol-Myers Squibb Receives FDA Approval of PRAVIGARD(TM) PAC (Buffered Aspirin and Pravastatin Sodium) Tablets
Jun 19, 03
17:11 ET	First Pediatric HIV/AIDS Center to Open in Botswana With Major Support From Bristol-Myers Squibb's Secure the Future Program
Jun 10, 03
17:53 ET	Bristol-Myers Squibb Announces Dividend
Jun 05, 03
16:49 ET	ImClone Systems and Bristol-Myers Squibb Meet With The FDA To Discuss ERBITUX(TM) (cetuximab) Regulatory Filing
Jun 04, 03
08:31 ET	Relief for Tension Headache Pain - Bristol-Myers Squibb Launches Excedrin(R) Tension Headache -
Jun 02, 03
09:03 ET	Bristol-Myers Squibb Epothilone Phase II Findings Show Activity in Metastatic Breast Cancer and Non-Small Cell Lung Cancer
May 20, 03
18:00 ET	Results From New Clinical Studies: Aripiprazole Significantly Improved Symptoms of Acute Bipolar Mania
May 19, 03
18:00 ET	Aripiprazole Demonstrates Better Weight Change Profile, Comparable Efficacy In Schizophrenia Compared to Olanzapine in New Study
May 13, 03
17:49 ET	FDA Antiviral Advisory Committee Recommends Approval For Bristol-Myers Squibb's Investigational Protease Inhibitor Reyataz(TM)(Atazanavir)
May 02, 03
11:14 ET	Bristol-Myers Squibb Company Announces Acquisition of Only FDA-Approved Short-Term Treatment for Apnea of Prematurity
Apr 29, 03
08:35 ET	Bristol-Myers Squibb Announces First Quarter Sales and Earnings For 2003
Apr 24, 03
10:27 ET	Bristol-Myers Squibb to Announce First Quarter Earnings on April 29, 2003
Apr 14, 03
11:03 ET	Bristol-Myers Squibb Announces U.S. Food And Drug Administration Approval Of Glucophage(R) XR (Metformin HCl Extended Release Tablets) 750 MG TABLET
Apr 02, 03
11:45 ET	International Analyses Show Plavix(R)/Iscover(R) (Clopidogrel Bisulphate) Has A Favorable Cost Effectiveness Ratio for ACS Patients Without ST-Segment Elevation (Unstable Angina Or Non Q-Wave MI); Data presented at American College of Cardiology 52nd Annu
Apr 01, 03
00:30 ET	Clopidogrel Studied in One of the Largest Clinical Trial Programs in the Fight Against Atherothrombosis
Mar 18, 03
22:08 ET	Bristol-Myers Squibb Files Restatement Documents With the Securities and Exchange Commission
Mar 10, 03
08:14 ET	Bristol-Myers Squibb Announces Restatement, Reports 2002 Full-Year Results and Reiterates Earnings Guidance for 2003
Mar 07, 03
12:00 ET	Bristol-Myers Squibb Announces Agreements With State Attorneys General And Federal Trade Commission
Mar 05, 03
11:06 ET	Minority Students from Nation's Top Medical Schools Discuss Health Disparities and Medical Careers with High School Students
Mar 04, 03
16:49 ET	Bristol-Myers Squibb Announces Dividend
Feb 27, 03
08:29 ET	Bristol-Myers Squibb to Announce Results of Restatement and 2002 Earnings On March 10, 2003
Feb 25, 03
09:00 ET	Supplemental New Drug Application (sNDA) for Long-Term Schizophrenia Treatment Submitted for ABILIFY(TM) (aripiprazole)
Jan 28, 03
10:58 ET	Bristol-Myers Squibb Announces Injectable Acetaminophen Licencing Agreement; - Agreement Expands Existing Pain Management Portfolio -
Jan 17, 03
07:30 ET	Bristol-Myers Squibb Provides Earnings Guidance For 2003
Jan 07, 03
10:44 ET	Bristol-Myers Squibb to Settle Antitrust Litigation
Dec 03, 02
18:05 ET	Bristol-Myers Squibb Board of Directors Declares Dividend
Nov 18, 02
10:44 ET	ABILIFY(TM) (Aripiprazole) Approved by U.S. Food and Drug Administration For Treatment of Schizophrenia
10:40 ET	PROSPER - The PROspective Study of Pravastatin in the Elderly at Risk
10:39 ET	Landmark Three-Year Clinical Trial Confirms for the First Time the Benefit of Pravastatin in Reducing the Risk of Heart Attack and Coronary Death in Older Patients
Nov 15, 02
16:40 ET	ABILIFY(TM) (aripiprazole) Approved By U.S. Food and Drug Administration For Treatment of Schizophrenia
08:28 ET	Bristol-Myers Squibb Company Announces the Expected Timing For Filing Its Third Quarter 2002 10-Q
Nov 06, 02
15:36 ET	Bristol-Myers Squibb Announces New Senior Leadership Team - New and Recent Hires Shape Process of Management Restructure -
Oct 31, 02
11:25 ET	U.S. Food and Drug Administration Approves Pravachol (R) (Pravastatin Sodium) for Use in Pediatric Patients
Oct 26, 02
09:30 ET	Data Show Bristol-Myers Squibb's BMS-188667 (CTLA4Ig), An Investigational Costimulation Blocker, Provided Improvement in Rheumatoid Arthritis Activity When Added to Methotrexate Therapy
09:30 ET	Data Suggest Bristol-Myers Squibb Investigational Costimulation Blocker, BMS-188667 (CTLA4Ig), May Have Potential in Rheumatoid Arthritis Patients Inadequately Responding to Etanercept Alone
Oct 24, 02
09:24 ET	Bristol-Myers Squibb Company to Restate Sales and Earnings For Periods Affected by Inventory Buildup in US Pharmaceuticals Unit
Oct 22, 02
09:57 ET	Bristol-Myers Squibb Receives FDA Approval of Metaglip(TM) (Glipizide and Metformin HCl Tablets) for Type 2 Diabetes
Oct 21, 02
09:03 ET	Bristol-Myers Squibb Appoints James Palmer to Position of Chief Scientific Officer
Oct 11, 02
18:49 ET